4aw5
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | [[ | + | ==Complex of the EphB4 kinase domain with an oxindole inhibitor== |
| + | <StructureSection load='4aw5' size='340' side='right' caption='[[4aw5]], [[Resolution|resolution]] 2.33Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4aw5]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4AW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4AW5 FirstGlance]. <br> | ||
| + | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=30K:(3Z)-5-[(1-ETHYLPIPERIDIN-4-YL)AMINO]-3-[(5-METHOXY-1H-BENZIMIDAZOL-2-YL)(PHENYL)METHYLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE'>30K</scene><br> | ||
| + | <tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2bba|2bba]], [[2vwu|2vwu]], [[2vwv|2vwv]], [[2vww|2vww]], [[2vwx|2vwx]], [[2vwy|2vwy]], [[2vwz|2vwz]], [[2vx0|2vx0]], [[2vx1|2vx1]], [[2x9f|2x9f]], [[2xvd|2xvd]]</td></tr> | ||
| + | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr> | ||
| + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4aw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4aw5 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4aw5 RCSB], [http://www.ebi.ac.uk/pdbsum/4aw5 PDBsum]</span></td></tr> | ||
| + | <table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models. | ||
| - | + | The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.,Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR, Le DT, Mac M, Parks JJ, Qian F, Rodriquez M, Stout TJ, Till JH, Won KA, Wu X, Michael Yakes F, Yu P, Zhang W, Zhao Y, Lamb P, Nuss JM, Xu W Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. Epub 2012 Jun 16. PMID:22765894<ref>PMID:22765894</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| + | </div> | ||
| - | + | ==See Also== | |
| - | + | *[[Ephrin receptor|Ephrin receptor]] | |
| - | == | + | == References == |
| - | [[ | + | <references/> |
| - | + | __TOC__ | |
| - | == | + | </StructureSection> |
| - | < | + | |
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Receptor protein-tyrosine kinase]] | [[Category: Receptor protein-tyrosine kinase]] | ||
Revision as of 08:06, 5 June 2014
Complex of the EphB4 kinase domain with an oxindole inhibitor
| |||||||||||
